BRIEF—New chief medical officer at uniQure

Dutch gene therapy company uniQure has appointed Walid Abi-Saab as chief medical officer, replacing Ricardo Dolmetsch, who will become president and chief scientific officer.

Dr Abi-Saab has more than 20 years of experience in global drug development, most recently as chief medical officer at Galapagos. Before that he was group vice president for global clinical development at rare disease company Shire.

Dr Dolmetsch will continue to lead all research, non-clinical research, and vector and enabling technology.

uniQure is advancing AMT-130 in Huntington’s disease and looking to move other candidates, including AMT-260 in refractory temporal lobe epilepsy and AMT-162 in SOD1 ALS, into clinical development.